论文部分内容阅读
目的研究GP方案联合重组人血管内皮抑制素注射液(恩度)治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法 64例晚期非小细胞肺癌患者随机分为对照组和治疗组,各32例,按GP+恩度(治疗组)和GP(对照组)方案化疗2个周期。对比并分析两组的临床效果。结果治疗组患者的有效率为65.6%,疾病控制率为96.9%,症状缓解率为81.3%,生活质量改善率为65.6%,明显优于对照组患者的40.6%、75.0%、56.3%和40.6%(P<0.05),而不良反应方面两组比较差异无统计学意义(P>0.05)。结论 GP方案联合恩度能显著提升晚期NSCLC患者的有效率,且不良反应较轻,安全可靠,值得在临床上推广应用。
Objective To study the clinical efficacy of GP regimen combined with recombinant human endostatin injection (Endo) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Sixty - four patients with advanced non - small cell lung cancer were randomly divided into control group and treatment group, with 32 cases in each group. The patients were treated with GP + Endu (treatment group) and GP (control group) regimen for 2 cycles. The clinical effects of the two groups were compared and analyzed. Results The effective rate of the treatment group was 65.6%, the disease control rate was 96.9%, the symptom relief rate was 81.3%, the quality of life improvement rate was 65.6%, which was significantly better than that of the control group 40.6%, 75.0%, 56.3% and 40.6 % (P <0.05), while there was no significant difference between the two groups in adverse reactions (P> 0.05). Conclusion The combination of GP regimen and Endue can significantly improve the efficiency of patients with advanced NSCLC, and the adverse reactions are mild, safe and reliable, which is worth popularizing and applying in clinic.